Thymuskin: Clinical Evidence for Hair Growth & Loss Treatment

Thymuskin is a hair growth product originally developed to prevent hair loss in patients undergoing chemotherapy or radiation treatments. Thymuskin is now marketed for treatment of other hair loss conditions, including alopecia and hair loss due to genetic traits.

Studies

• The U.S. Research website lists a number of clinical studies evaluating the effectiveness of Thymuskin in men and women with various types of hair loss. The studies showed similar results in both male and female participants.

Results

• One study of female alopecia patients showed that 73 percent had new hair growth after six months of using Thymuskin. In another study using Thymuskin, 31 percent of men and 72 percent of women with alopecia had no hair loss and new hair growth after six months, and 61 percent of men and 21 percent of women had no hair loss and no new growth. In the same study, 8 percent of men and 7 percent of women still had hair loss with no new growth.

Considerations

• According to the Health Development Advice website, the U.S. Food and Drug Administration (FDA) has approved Thymuskin as a cosmetic product for treating and thickening hair for aesthetic purposes only. Thymuskin is not FDA-approved for stimulating actual regrowth of hair.